AACR 에 이어 ASCO 에서도 Incyte 의 epacadostat 이 주목을 받았다.

ASCO abstract 에서 epacadostat 으로 105개의 연구결과가 검색 되었고, 이 중 주목할만한 내용 몇 개를 보자면,

1. Epacadostat + Pembrolizumab in NSCLC

ORR (CR+PR) and DCR (CR+PR+SD) were 35% (14/40; 14 PR) and 60% (24/40; 10 SD), respectively. 대부분의 환자가 1차 chemo 환자라는 점에서, 그리고 pembrolizumab 이 1st-line therapy 가 가능하다는 점에서, epacadostat combination 이 1st-line 으로 가게되면 더욱 response rate 가 올라갈 것으로 기대. 임상 3상 진행 예정.

http://abstracts.asco.org/199/AbstView_199_181148.html

2. Epa + Pemb in advanced RCC

ORR (CR+PR) and DCR (CR+PR+SD) for pts with 0–1 prior tx was 47% (9/19; 1 CR, 8 PR) and 58% (11/19; 1 CR, 8 PR, 2 SD), respectively; for pts with ≥2 prior tx, ORR and DCR were 0% and 36% (4/11; all SD). 역시 임상 3상 예정.

http://abstracts.asco.org/199/AbstView_199_184165.html

3. E + P in advanced urothelial carcinoma

for pts with 0–1 prior line of therapy for advanced disease, ORR and DCR were 37% (10/27) and 63% (17/27). 임상 3상 예정.

http://abstracts.asco.org/199/AbstView_199_183204.html

4. E + P in Triple-negative BC & Ovarian cancer

For TNBC pts, ORR (CR+PR) was 10% (n = 4; all PR) and DCR (CR+PR+SD) was 36% (n = 14; 10 SD); ORR and DCR for pts with ≤2 prior tx were 12% (n = 2) and 29% (n = 5), respectively, and for ≥3 prior tx were 9% (n = 2) and 41% (n = 9).

For OVC pts, ORR was 8% (n = 3; all PR) and DCR was 35% (n = 13; 10 SD); ORR and DCR for pts with ≤2 prior tx were 13% (n = 1) and 25% (n = 2), and for ≥3 prior tx were 7% (n = 2) and 38% (n = 11)

TNBC, OVC 에서의 반응률은 좀 낮은 편.

http://abstracts.asco.org/199/AbstView_199_183215.html

5. E + P in SCCHN

Of 36 efficacy-evaluable pts, 81% (n = 29) received 1–2 prior lines of tx and 19% (n = 7) received ≥3 prior lines of tx. ORR (CR+PR) and DCR (CR+PR+SD) for pts with 1–2 prior tx were 34% (2 CR, 8 PR) and 62% (8 SD), respectively; for pts with ≥3 prior tx, ORR and DCR were 14% (1 PR) and 43% (2 SD). Response was observed regardless of HPV status.

역시 임상 3상 예정.

http://abstracts.asco.org/199/AbstView_199_184180.html

6. Epacadostat + Nivolumab in advanced solid tumors

1) Of 30 MEL pts, 8 were treated with E 100 mg and 22 were more recently enrolled and treated with E 300 mg. ORR (CR+PR) and DCR in MEL pts treated with E 100 mg were 75% (n = 6; all PR) and 100% (n = 8; 2 SD), respectively. Preliminary DCR in MEL pts treated with E 300 mg was 64% (n = 14).

2) Of 29 OVC pts, 18 were treated with E 100 mg and 11 with E 300 mg.ORR and DCR for OVC pts treated with E 100 mg were 11% (n = 2; 2 PR) and 28% (n = 5; 3 SD); for 11 OVC pts treated with E 300 mg, ORR and DCR were 18% (n = 2; 2 PR) and 36% (n = 4; 2 SD).

3) For 25 CRC pts (all E 100 mg), ORR and DCR were 4% (n = 1; PR) and 24% (n = 6; 5 SD)

http://abstracts.asco.org/199/AbstView_199_184081.html

일단 safety 측면에서 CTLA-4 antibody를 능가한다고 하니, 내년쯤 PD-(L)1 의 combi partner 로 승인 받지 않을까